Fairfield, CT - (February 25, 2009) - Competitive Technologies, Inc. (NYSE Alternext US: CTT) announced today that the US Food and Drug Administration (FDA) has issued a 510(k) letter of authorization allowing US sales of CTT's pain therapy medical device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The FDA authorization expands CTT's opportunities for sales in both the US and globally. CTT has exclusive worldwide rights to this patented device. The CTT device also has Medical Device CE certification from the European Union allowing sales throughout Europe and several other countries.
"Our initial focus in the U.S. will be to the major US cancer centers, and to select medical equipment distributors for sales to hospitals, pain clinics, hospice centers and pain management specialists," said Aris D. Despo, CTT's Executive VP, Business Development. "The FDA authorization and our international distributors are significant steps in CTT's global commercialization of this breakthrough medical device, which offers relief to patients suffering extreme pain. Our device provides a valuable tool to the clinician in offering an effective treatment program that can positively impact the quality of life of a patient who has not otherwise responded to standard therapeutic protocols, including morphine."
In addition to the Country-exclusive distribution rights granted to Life Epistéme srl for each of 29 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania, earlier agreements granted Country-exclusive distribution rights to Excel Life Sciences, Inc. for India, to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh. The review and selection process for distributors in additional countries is continuing. The U.S. Department of Commerce estimates the world market for medical devices at $248 billion. The United States represents about half that market.
"The FDA's authorization brings CTT to the forefront in providing a solution to the needs of patients and the improvement of palliative healthcare in the U.S. and globally," said John B. Nano, CTT's Chairman, President and CEO. "This technology is a prime example of our strategy to connect clinical science to patient care. We believe that revenue and profits from the pain management technology will significantly increase CTT's market capitalization."
Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the technology was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community™. The unit, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT's partner, GEOMC Co. Ltd. of Korea is manufacturing the device commercially for worldwide distribution. For more information on the device, visit www.CalmareTT.com.
The device has been used on over 3,000 patients in Europe, including at the Pain Management Center at Tor-Vergata University Medical Center in Rome (http://www.ptvonline.it/uo_ter_ant_ing.asp)
., and at Fondazione Parco Biomedico San Raffaele in Rome (www.scienceparkrome.eu)
About Calmare Therapeutics
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.